Complete Omics’ announced a collaboration with ErVaccine Technologies, a pharmaceutical company headquartered in Lyon, Rhone-Alpes, France, on a neoantigen validation and quantification project.
Ervaccine Technologies a developer of next-generation cancer vaccines that targets endogenous retroviruses. Complete Omics is proud to work with ErVaccine to leverage our Valid-NEO platform for personalized cancer therapeutics.